Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oncology Pharma Inc
(OP:
ONPH
)
0.0001
UNCHANGED
Last Price
Updated: 9:30 AM EDT, Aug 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,000
Open
0.0001
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0001
Today's Range
0.0001 - 0.0001
52wk Range
0.0001 - 0.4300
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly
March 23, 2024
Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency.
Via
Benzinga
Topics
Fraud
Lawsuit
Exposures
Criminal
Legal
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
July 12, 2022
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the...
From
Oncology Pharma Inc.
Via
AccessWire
Performance
YTD
-66.67%
-66.67%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-50.00%
-50.00%
1 Year
-99.87%
-99.87%
More News
Read More
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
June 29, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Exposures
Product Safety
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
June 08, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 09, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 13, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Reports on Progress with Ribera Solutions
March 02, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
February 23, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Expands on Feasibility Studies and Data
February 17, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
February 14, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
February 08, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma's New Year Update
January 10, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Meeting Towards Future Developments
December 17, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Oncology Pharma Year End Review and Outlook
December 09, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma Research and Vision
November 30, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 08, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 27, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 15, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 12, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 13, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 23, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 19, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 20, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 30, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 15, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.